Bolt Biotherapeutics' $120M Move to Advance Antibody Platform
Bolt Biotherapeutics acquires Prana Therapies and raises $120 million to advance its antibody platform, potentially increasing funding to $180 million. This move supports operations through 2028, with implications for AECM professionals in biotech construction and manufacturing.